Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $207.32, giving the company a market capitalization of 499.36B. It carries a P/E multiple of 19.92 and pays a dividend yield of 2.5%.
On 2025-12-23, Johnson & Johnson(JNJ) stock moved within a range of $205.50 to $208.08. With shares now at $207.32, the stock is trading +0.9% above its intraday low and -0.4% below the session's peak.
Trading volume for Johnson & Johnson(JNJ) stock has reached 7.62M, versus its average volume of 10.24M.
The stock's 52-week range extends from a low of $140.68 to a high of $215.19.
The stock's 52-week range extends from a low of $140.68 to a high of $215.19.
JNJ News
A Baltimore jury on Monday ordered Johnson & Johnson (NYSE:JNJ) and its subsidiaries to pay over $1.5 billion to a woman, who claimed that decades of exposure t...
Wondering if Johnson & Johnson is still a buy at around $206 a share, or if the easy gains are already behind it? This breakdown will help you decide whether th...
Johnson & Johnson (NYSE:JNJ) has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder....
Analyst ratings
56%
of 27 ratingsMore JNJ News
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson (NYSE:JNJ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first...
Johnson & Johnson recently received U.S. FDA approval for RYBREVANT FASPRO™, the first subcutaneous amivantamab-based therapy for EGFR‑mutated non‑small cell lu...
Goldman Sachs analyst Asad Haider raised the firm’s price target on Johnson & Johnson to $240 from $213 and keeps a Buy rating on the shares. Claim 50% Off Tip...
Johnson & Johnson “announced that the FDA approved RYBREVANT FASPRO, amivantamab and hyaluronidase-lpuj, the first and only subcutaneously administered therapy...